High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers

Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression. The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breas...

Full description

Bibliographic Details
Main Authors: Sigurður Ingvarsson 1956-, Guðný Eiriksdóttir 1950-, Rósa Björk Barkardóttir 1958-, Bjarni A. Agnarsson 1952-, Guðrún Jóhannesdóttir 1957-, Kristrún Auður Ólafsdóttir 1941-, Valgarður Egilsson 1940-
Other Authors: Háskóli Íslands
Format: Article in Journal/Newspaper
Language:English
Published: 1998
Subjects:
Online Access:http://hdl.handle.net/1946/20777
Description
Summary:Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression. The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5). Loss of heterozygosity (LOH) was detected in 23 of the 27 tumours (85%). The majority of tumours manifesting LOH had lost a large region on 17p, although a more restricted loss, including the TP53 locus was seen in a few tumours. Positive p53 immunostaining was observed in 18 of 26 tumours (69%). However, mutations in the TP53 gene were detected in only three tumours (11%), including a missense (codon 139) and a nonsense mutation (codon 306) in two tumours with moderate p53 expression and a frameshift deletion (codon 182) in a tumour with no detectable p53 expression. Positive p53 immunostaining, mainly weak, was observed in 16 of the 24 tumours (66%) without TP53 mutation. The high frequency of LOH at chromosome 17p13 suggests that one or more genes from this region are involved in the development of BRCA2-induced breast cancer. The frequent finding of weak overexpression of, presumably wild type p53 protein, suggests an alternative mechanism of TP53 involvement specific to these tumours. This work was financially supported by the Nordic Cancer Union, The Icelandic Cancer Society, The Memorial Fund of Bergthora Magnusdottir and Jakob B Bjarnason, the Icelandic Research Council, the Science Fund of the University Hospital of Iceland and the Research Fund of the University of Iceland.